Ignite Creation Date:
2025-12-24 @ 4:27 PM
Ignite Modification Date:
2025-12-28 @ 12:29 PM
Study NCT ID:
NCT06130566
Status:
COMPLETED
Last Update Posted:
2025-11-24
First Post:
2023-11-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003876', 'term': 'Dermatitis, Atopic'}], 'ancestors': [{'id': 'D012873', 'term': 'Skin Diseases, Genetic'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D003872', 'term': 'Dermatitis'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D017443', 'term': 'Skin Diseases, Eczematous'}, {'id': 'D006969', 'term': 'Hypersensitivity, Immediate'}, {'id': 'D006967', 'term': 'Hypersensitivity'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 601}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2023-11-08', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-11', 'completionDateStruct': {'date': '2025-11-13', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-11-19', 'studyFirstSubmitDate': '2023-11-08', 'studyFirstSubmitQcDate': '2023-11-08', 'lastUpdatePostDateStruct': {'date': '2025-11-24', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2023-11-14', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-07-23', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24', 'timeFrame': 'Week 24', 'description': 'The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).'}, {'measure': 'EU, EU reference countries, and Japan: Proportion of participants reaching 75% reduction from baseline in Eczema Area and Severity Index (EASI) score (EASI-75) at Week 24', 'timeFrame': 'Week 24', 'description': 'The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.'}, {'measure': 'US and US reference countries: Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24', 'timeFrame': 'Week 24', 'description': 'The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).'}], 'secondaryOutcomes': [{'measure': 'Proportion of participants reaching EASI-75 at Week 24 (for US and US reference countries only)', 'timeFrame': 'Week 24', 'description': 'The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score.'}, {'measure': 'Proportion of participants with vIGA-AD 0 (clear) or 1 (almost clear) with presence of only barely perceptible erythema (no induration/papulation, no lichenification, no oozing or crusting) and a reduction from baseline of ≥2 points', 'timeFrame': 'Baseline to Week 24', 'description': 'The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).'}, {'measure': 'Proportion of participants with ≥4-point reduction in weekly average of daily Peak Pruritus-Numerical Rating Scale (PP-NRS) from baseline in participants with baseline weekly average of daily PP-NRS ≥4', 'timeFrame': 'Baseline to Week 24', 'description': 'The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.'}, {'measure': 'Proportion of participants reaching EASI-75', 'timeFrame': 'Baseline to Week 20', 'description': 'The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score.'}, {'measure': 'Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points', 'timeFrame': 'Baseline to Week 20', 'description': 'The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).'}, {'measure': 'Proportion of participants reaching EASI-90', 'timeFrame': 'Baseline to Week 24', 'description': 'The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-90 is 90% reduction from baseline in EASI score.'}, {'measure': 'Proportion of participants reaching EASI-100', 'timeFrame': 'Baseline to Week 24', 'description': 'The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-100 is 100% reduction from baseline in EASI score.'}, {'measure': 'Proportion of participants with PP-NRS 0 or 1', 'timeFrame': 'Baseline to Week 24', 'description': 'The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.'}, {'measure': 'Change in Dermatology Life Quality Index (DLQI) from baseline in participants with age ≥16 years old', 'timeFrame': 'Baseline to Week 24', 'description': 'The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.'}, {'measure': 'Proportion of participants with a reduction in DLQI ≥4 from baseline in participants with age ≥16 years old and with DLQI baseline ≥4', 'timeFrame': 'Baseline to Week 24', 'description': 'The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.'}, {'measure': 'Change in Children Dermatology Life Quality Index (CDLQI) from baseline in participants with age ≥12 to <16 years old', 'timeFrame': 'Baseline to Week 24', 'description': 'The CDLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in children aged 4-\\<16 years. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.'}, {'measure': 'Proportion of participants with a reduction in CDLQI ≥6 from baseline in participants with age ≥12 to <16 years old and with CDLQI baseline ≥6', 'timeFrame': 'Baseline to Week 24', 'description': 'The CDLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in children aged 4-\\<16 years. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.'}, {'measure': 'Change in Hospital Anxiety Depression Scale (HADS) from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The HADS is 14-item questionnaire with two subscales: anxiety \\& depression. Each subscale (anxiety \\& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.'}, {'measure': 'Proportion of participants with HADS subscale Anxiety (HADS-A) <8 in participants with baseline HADS-A ≥8', 'timeFrame': 'Baseline to Week 24', 'description': 'HADS-A score ranges 0-21 with higher score indicating a poorer state.'}, {'measure': 'Proportion of participants with HADS subscale Depression (HADS-D) <8 in participants with HADS-D baseline ≥8', 'timeFrame': 'Baseline to Week 24', 'description': 'HADS-D score ranges 0-21 with higher score indicating a poorer state.'}, {'measure': 'Absolute change in weekly average of daily Skin Pain-Numerical Rating Scale (SP-NRS) from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.'}, {'measure': 'Proportion of participants with a reduction in weekly average of daily SP-NRS ≥4 from baseline in participants with baseline weekly average of daily SP-NRS ≥4', 'timeFrame': 'Baseline to Week 24', 'description': 'The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.'}, {'measure': 'Percent change in weekly average of daily SP-NRS from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.'}, {'measure': 'Proportion of participants with vIGA-AD 0', 'timeFrame': 'Week 24', 'description': 'The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).'}, {'measure': 'Absolute change in weekly average of daily Sleep Disturbance-Numerical Rating Scale (SD-NRS) from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.'}, {'measure': 'Proportion of participants with a reduction in weekly average of daily SD-NRS ≥3 from baseline in participants with Baseline weekly average of daily SD-NRS ≥3', 'timeFrame': 'Baseline to Week 24', 'description': 'The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.'}, {'measure': 'Percent change in weekly average of daily SD-NRS', 'timeFrame': 'Baseline to Week 24', 'description': 'The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.'}, {'measure': 'Percent change in EASI score from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.'}, {'measure': 'Percent change in weekly average of daily PP-NRS from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.'}, {'measure': 'Absolute change in weekly average of daily PP-NRS from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.'}, {'measure': 'Proportion of participants reaching EASI-50', 'timeFrame': 'Baseline to Week 24', 'description': 'The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-50 is 50% reduction from baseline in EASI score.'}, {'measure': 'Proportion of participants with EASI ≤7', 'timeFrame': 'Baseline to Week 24', 'description': 'The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.'}, {'measure': 'Change in percent Body Surface Area (BSA) affected by AD from baseline', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Percent change in Scoring Atopic Dermatitis (SCORAD) index from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).'}, {'measure': 'Absolute change in SCORAD index from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).'}, {'measure': 'Proportion of participants with a reduction in SCORAD ≥ 8.7 points from baseline in participants with baseline SCORAD score ≥ 8.7', 'timeFrame': 'Baseline to Week 24', 'description': 'The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).'}, {'measure': 'Change in Patient Oriented Eczema Measure (POEM) from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a 5-point scale; 0 (no days) to 4 (every day in the last week). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (very severe). Higher scores indicated more severe disease and poor quality of life.'}, {'measure': 'Proportion of participants with a reduction in POEM ≥4 from baseline in participants with POEM Baseline ≥4', 'timeFrame': 'Baseline to Week 24', 'description': 'The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a 5-point scale; 0 (no days) to 4 (every day in the last week). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (very severe). Higher scores indicated more severe disease and poor quality of life.'}, {'measure': 'Proportion of participants with rescue medication use', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Percentage of participants who experienced Treatment-Emergent Adverse Events (TEAEs), experienced Treatment-Emergent Serious Adverse Events (TESAEs) and/or Treatment-Emergent Adverse Events of Special Interest (AESI)', 'timeFrame': 'Baseline to Week 40'}, {'measure': 'Serum amlitelimab concentrations', 'timeFrame': 'Baseline to Week 40'}, {'measure': 'Incidence of antidrug antibodies (ADAs) of amlitelimab', 'timeFrame': 'Baseline to Week 40'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Dermatitis Atopic']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://sanofi.trialsummaries.com/Study/StudyDetails?id=25523&tenant=MT_SNY_9011', 'label': 'EFC17559 Plain Language Results Summary'}]}, 'descriptionModule': {'briefSummary': 'This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.\n\nThe purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for SC injection compared with placebo in participants with moderate to severe AD aged 12 years and older.\n\nStudy details include:\n\nAt the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY).\n\nFor participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up.\n\nFor participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period.\n\nThe total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600\\] (ESTUARY).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '12 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Participants must be 12 years of age (when signing informed consent form)\n* Diagnosis of AD for at least 1 year (defined by the American Academy of Dermatology Consensus Criteria)\n* Documented history (within 6 months before screening) of either inadequate response or inadvisability to topical treatments, and/or inadequate response to systemic therapies (within 12 months before screening)\n* v-IGA-AD of 3 or 4 at baseline visit\n* EASI score of 16 or higher at baseline\n* AD involvement of 10% or more of BSA at baseline\n* Weekly average of daily PP-NRS of ≥ 4 at baseline visit.\n* Able and willing to comply with requested study visits and procedures\n* Body weight ≥25 kg\n\nExclusion Criteria:\n\n* Skin co-morbidity that would adversely affect the ability to undertake AD assessments\n* Known history of or suspected significant current immunosuppression\n* Any malignancies or history of malignancies prior to baseline (with the exception of non-melanoma skin cancer excised and cured \\>5 years prior to baseline)\n* History of solid organ or stem cell transplant\n* Any active or chronic infection including helminthic infection requiring systemic treatment within 4 weeks prior to baseline (1 week in the event of superficial skin infections)\n* Positive for human immunodeficiency virus (HIV), Hepatitis B or hepatitis C at screening visit\n* Having active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB\n* Having received any of the specified therapy within the specified timeframe(s) prior to the baseline visit\n* In the Investigator's opinion, any clinically significant laboratory results or protocol specified laboratory abnormalities at screening\n* History of hypersensitivity or allergy to any of the excipients or investigational medicinal product (IMP)\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial"}, 'identificationModule': {'nctId': 'NCT06130566', 'acronym': 'COAST 1', 'briefTitle': 'A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis', 'organization': {'class': 'INDUSTRY', 'fullName': 'Sanofi'}, 'officialTitle': 'A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis', 'orgStudyIdInfo': {'id': 'EFC17559'}, 'secondaryIdInfos': [{'id': 'U1111-1275-9715', 'type': 'REGISTRY', 'domain': 'ICTRP'}, {'id': '2022-501196-41', 'type': 'REGISTRY', 'domain': 'CTIS'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Amlitelimab dose 1', 'description': 'Subcutaneous injection as per protocol', 'interventionNames': ['Drug: Amlitelimab']}, {'type': 'EXPERIMENTAL', 'label': 'Amlitelimab dose 2', 'description': 'Subcutaneous injection as per protocol', 'interventionNames': ['Drug: Amlitelimab']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Subcutaneous injection as per protocol', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'Amlitelimab', 'type': 'DRUG', 'otherNames': ['SAR445229'], 'description': 'Injection solution SC injection', 'armGroupLabels': ['Amlitelimab dose 1', 'Amlitelimab dose 2']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Injection solution SC injection', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85260', 'city': 'Scottsdale', 'state': 'Arizona', 'country': 'United States', 'facility': 'Scottsdale Clinical Trials- Site Number : 8401149', 'geoPoint': {'lat': 33.50921, 'lon': -111.89903}}, {'zip': '92708', 'city': 'Fountain Valley', 'state': 'California', 'country': 'United States', 'facility': 'First OC Dermatology- Site Number : 8401025', 'geoPoint': {'lat': 33.70918, 'lon': -117.95367}}, {'zip': '94538', 'city': 'Fremont', 'state': 'California', 'country': 'United States', 'facility': 'Center for Dermatology Clinical Research- Site Number : 8401018', 'geoPoint': {'lat': 37.54827, 'lon': -121.98857}}, {'zip': '94549', 'city': 'Lafayette', 'state': 'California', 'country': 'United States', 'facility': 'Sunwise Clinical Research- Site Number : 8401022', 'geoPoint': {'lat': 37.88576, 'lon': -122.11802}}, {'zip': '91606', 'city': 'North Hollywood', 'state': 'California', 'country': 'United States', 'facility': 'Carbon Health - North Hollywood - NoHo West- Site Number : 8401218', 'geoPoint': {'lat': 34.17223, 'lon': -118.37897}}, {'zip': '91325', 'city': 'Northridge', 'state': 'California', 'country': 'United States', 'facility': 'Northridge Clinical Trials - Northridge- Site Number : 8401080', 'geoPoint': {'lat': 34.22834, 'lon': -118.53675}}, {'zip': '33172', 'city': 'Doral', 'state': 'Florida', 'country': 'United States', 'facility': 'St Jude Clinical Research- Site Number : 8401287', 'geoPoint': {'lat': 25.81954, 'lon': -80.35533}}, {'zip': '33919', 'city': 'Fort Myers', 'state': 'Florida', 'country': 'United States', 'facility': 'Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8401286', 'geoPoint': {'lat': 26.62168, 'lon': -81.84059}}, {'zip': '33012', 'city': 'Hialeah', 'state': 'Florida', 'country': 'United States', 'facility': 'Direct Helpers Research Center- Site Number : 8401056', 'geoPoint': {'lat': 25.8576, 'lon': -80.27811}}, {'zip': '33021', 'city': 'Hollywood', 'state': 'Florida', 'country': 'United States', 'facility': 'Encore Medical Research- Site Number : 8401030', 'geoPoint': {'lat': 26.0112, 'lon': -80.14949}}, {'zip': '33173', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Florida International Research Center- Site Number : 8401091', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33173', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Miami Dermatology and Laser Research- Site Number : 8401086', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '32806', 'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'facility': 'Clinical Neuroscience Solutions - Orlando - South Delaney Avenue- Site Number : 8401035', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '30040', 'city': 'Cumming', 'state': 'Georgia', 'country': 'United States', 'facility': 'Cleaver Medical Group Dermatology- Site Number : 8401139', 'geoPoint': {'lat': 34.20732, 'lon': -84.14019}}, {'zip': '31217', 'city': 'Macon', 'state': 'Georgia', 'country': 'United States', 'facility': 'Skin Care Physicians of Georgia - Macon- Site Number : 8401034', 'geoPoint': {'lat': 32.84069, 'lon': -83.6324}}, {'zip': '31792', 'city': 'Thomasville', 'state': 'Georgia', 'country': 'United States', 'facility': 'Javara Research - Thomasville- Site Number : 8401189', 'geoPoint': {'lat': 30.83658, 'lon': -83.97878}}, {'zip': '30291', 'city': 'Union City', 'state': 'Georgia', 'country': 'United States', 'facility': 'Rophe Adult & Pediatric Medicine- Site Number : 8401289', 'geoPoint': {'lat': 33.58706, 'lon': -84.54243}}, {'zip': '40217', 'city': 'Louisville', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Skin Sciences- Site Number : 8401039', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '70433', 'city': 'Covington', 'state': 'Louisiana', 'country': 'United States', 'facility': 'MedPharmics - Covington- Site Number : 8401137', 'geoPoint': {'lat': 30.47549, 'lon': -90.10042}}, {'zip': '70508', 'city': 'Lafayette', 'state': 'Louisiana', 'country': 'United States', 'facility': 'MedPharmics - Lafeyette- Site Number : 8401152', 'geoPoint': {'lat': 30.22409, 'lon': -92.01984}}, {'zip': '02114', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Massachusetts General Hospital- Site Number : 8401192', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '02492', 'city': 'Needham', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Metro Boston Clinical Partners- Site Number : 8401128', 'geoPoint': {'lat': 42.28343, 'lon': -71.23283}}, {'zip': '33122', 'city': 'Dearborn', 'state': 'Michigan', 'country': 'United States', 'facility': 'Revival Research - Doral- Site Number : 8401012', 'geoPoint': {'lat': 42.32226, 'lon': -83.17631}}, {'zip': '48202', 'city': 'Detroit', 'state': 'Michigan', 'country': 'United States', 'facility': 'Henry Ford Hospital- Site Number : 8401044', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'zip': '39157', 'city': 'Ridgeland', 'state': 'Mississippi', 'country': 'United States', 'facility': 'SKY Integrative Medical Center/SKYCRNG - Ridgeland- Site Number : 8401058', 'geoPoint': {'lat': 32.42848, 'lon': -90.13231}}, {'zip': '64506', 'city': 'Saint Joseph', 'state': 'Missouri', 'country': 'United States', 'facility': 'MediSearch Clinical Trials- Site Number : 8401140', 'geoPoint': {'lat': 39.76861, 'lon': -94.84663}}, {'zip': '68510', 'city': 'Lincoln', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Somnos Clinical Research- Site Number : 8401203', 'geoPoint': {'lat': 40.8, 'lon': -96.66696}}, {'zip': '14450', 'city': 'Fairport', 'state': 'New York', 'country': 'United States', 'facility': 'Universal Dermatology- Site Number : 8401224', 'geoPoint': {'lat': 43.09867, 'lon': -77.44194}}, {'zip': '10075', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Sadick Research Group - New York - Park Avenue- Site Number : 8401050', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10459', 'city': 'The Bronx', 'state': 'New York', 'country': 'United States', 'facility': 'CHEAR Center- Site Number : 8401123', 'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}, {'zip': '28277', 'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Onsite Clinical Solutions - Charlotte - Blakeney Park Drive- Site Number : 8401124', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'zip': '97201', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Oregon Medical Research Center- Site Number : 8401017', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '17011', 'city': 'Camp Hill', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Vial Health - DermDox Dermatology- Site Number : 8401031', 'geoPoint': {'lat': 40.23981, 'lon': -76.91997}}, {'zip': '19103', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Paddington Testing Company- Site Number : 8401041', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '19114', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Clinical Research of Philadelphia- Site Number : 8401193', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '29607', 'city': 'Greenville', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Tribe Clinical Research - 525 Verdae Boulevard- Site Number : 8401225', 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'zip': '75230', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Dermatology Treatment and Research Center- Site Number : 8401164', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '75254', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Skin Specialist of Addison- Site Number : 8401208', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '78218', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'Texas Dermatology and Laser Specialists- Site Number : 8401131', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '76092', 'city': 'Southlake', 'state': 'Texas', 'country': 'United States', 'facility': 'Stryde Research - Epiphany Dermatology- Site Number : 8401185', 'geoPoint': {'lat': 32.94124, 'lon': -97.13418}}, {'zip': '84663', 'city': 'Springville', 'state': 'Utah', 'country': 'United States', 'facility': 'Springville Dermatology - Springville- Site Number : 8401106', 'geoPoint': {'lat': 40.16523, 'lon': -111.61075}}, {'zip': '23502', 'city': 'Norfolk', 'state': 'Virginia', 'country': 'United States', 'facility': 'Virginia Dermatology & Skin Cancer Center- Site Number : 8401047', 'geoPoint': {'lat': 36.84681, 'lon': -76.28522}}, {'zip': '1028', 'city': 'Buenos Aires', 'state': 'Buenos Aires F.D.', 'country': 'Argentina', 'facility': 'Investigational Site Number : 0320023', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': 'T4000', 'city': 'SAN Miguel de Tucumã¡n', 'state': 'Tucumán Province', 'country': 'Argentina', 'facility': 'Investigational Site Number : 0320024'}, {'zip': '1012', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Investigational Site Number : 0320022', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': '1414', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Investigational Site Number : 0320010', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': '2145', 'city': 'Westmead', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Investigational Site Number : 0360010', 'geoPoint': {'lat': -33.80383, 'lon': 150.98768}}, {'zip': '4102', 'city': 'Woolloongabba', 'state': 'Queensland', 'country': 'Australia', 'facility': 'Investigational Site Number : 0360007', 'geoPoint': {'lat': -27.48855, 'lon': 153.03655}}, {'zip': '3002', 'city': 'Melbourne', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Investigational Site Number : 0360008', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'zip': '3004', 'city': 'Melbourne', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Investigational Site Number : 0360006', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'zip': '3844', 'city': 'Traralgon', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Investigational Site Number : 0361006', 'geoPoint': {'lat': -38.19528, 'lon': 146.5415}}, {'zip': '41820-020', 'city': 'Salvador', 'state': 'Estado de Bahia', 'country': 'Brazil', 'facility': 'Centro de Pesquisas da Clínica IBIS- Site Number : 0760002', 'geoPoint': {'lat': -12.97563, 'lon': -38.49096}}, {'zip': '65060-645', 'city': 'Bequimão', 'state': 'Maranhão', 'country': 'Brazil', 'facility': 'Hospital São Domingos- Site Number : 0760028', 'geoPoint': {'lat': -2.44889, 'lon': -44.7825}}, {'zip': '80060-900', 'city': 'Curitiba', 'state': 'Paraná', 'country': 'Brazil', 'facility': 'Hospital de Clinicas da Universidade Federal do Parana- Site Number : 0760022', 'geoPoint': {'lat': -25.42778, 'lon': -49.27306}}, {'zip': '80230-130', 'city': 'Curitiba', 'state': 'Paraná', 'country': 'Brazil', 'facility': 'PUC Trials- Nucleo de Pesquisa clinica da Escola de Medicina da PUCPR- Site Number : 0760023', 'geoPoint': {'lat': -25.42778, 'lon': -49.27306}}, {'zip': '90020-090', 'city': 'Porto Alegre', 'state': 'Rio Grande do Sul', 'country': 'Brazil', 'facility': 'Irmandade da Santa Casa de Misericórdia de Porto Alegre- Site Number : 0760005', 'geoPoint': {'lat': -30.03283, 'lon': -51.23019}}, {'zip': '18040-425', 'city': 'Sorocaba', 'state': 'São Paulo', 'country': 'Brazil', 'facility': 'Clinica de Alergia Martti Antila- Site Number : 0760006', 'geoPoint': {'lat': -23.50167, 'lon': -47.45806}}, {'zip': '22241-180', 'city': 'Rio de Janeiro', 'country': 'Brazil', 'facility': 'CCBR / IBPClin - Instituto Brasil de Pesquisa Clínica- Site Number : 0760018', 'geoPoint': {'lat': -22.90642, 'lon': -43.18223}}, {'zip': '09060-650', 'city': 'Santo André', 'country': 'Brazil', 'facility': 'Faculdade de Medicina do ABC- Site Number : 0760001', 'geoPoint': {'lat': -23.66389, 'lon': -46.53833}}, {'zip': '04020-060', 'city': 'São Paulo', 'country': 'Brazil', 'facility': 'Centro de Desenvolvimento em Estudos ClÌnicos Brasil- Site Number : 0760014', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '05403-000', 'city': 'São Paulo', 'country': 'Brazil', 'facility': 'Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760012', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': 'T5K 2V4', 'city': 'Edmonton', 'state': 'Alberta', 'country': 'Canada', 'facility': 'Investigational Site Number : 1240031', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'zip': 'V3R 6A7', 'city': 'Surrey', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'Investigational Site Number : 1240040', 'geoPoint': {'lat': 49.10635, 'lon': -122.82509}}, {'zip': 'L1S 7K8', 'city': 'Ajax', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Investigational Site Number : 1240033', 'geoPoint': {'lat': 43.85012, 'lon': -79.03288}}, {'zip': 'L8S 1G5', 'city': 'Hamilton', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Investigational Site Number : 1240055', 'geoPoint': {'lat': 43.25011, 'lon': -79.84963}}, {'zip': 'N6A 2C2', 'city': 'London', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Investigational Site Number : 1240029', 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'zip': 'L2H 1H5', 'city': 'Niagara Falls', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Investigational Site Number : 1241108', 'geoPoint': {'lat': 43.10012, 'lon': -79.06627}}, {'zip': 'K1H 7X8', 'city': 'Ottawa', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Investigational Site Number : 1240034', 'geoPoint': {'lat': 45.41117, 'lon': -75.69812}}, {'zip': 'M3B 3N1', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Investigational Site Number : 1240013', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'M5A 3R6', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Investigational Site Number : 1240035', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'J7Z 7E2', 'city': 'Saint-Jérôme', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Investigational Site Number : 1240043', 'geoPoint': {'lat': 45.78036, 'lon': -74.00365}}, {'zip': 'S4V 1R9', 'city': 'Regina', 'state': 'Saskatchewan', 'country': 'Canada', 'facility': 'Investigational Site Number : 1240028', 'geoPoint': {'lat': 50.45008, 'lon': -104.6178}}, {'zip': 'S7K 0H6', 'city': 'Saskatoon', 'state': 'Saskatchewan', 'country': 'Canada', 'facility': 'Investigational Site Number : 1240036', 'geoPoint': {'lat': 52.13238, 'lon': -106.66892}}, {'zip': '5311523', 'city': 'Osorno', 'state': 'Reg Metropolitana de Santiago', 'country': 'Chile', 'facility': 'Investigational Site Number : 1520009', 'geoPoint': {'lat': -40.57395, 'lon': -73.13348}}, {'zip': '7500587', 'city': 'Santiago', 'state': 'Reg Metropolitana de Santiago', 'country': 'Chile', 'facility': 'Investigational Site Number : 1520008', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '7580206', 'city': 'Santiago', 'state': 'Reg Metropolitana de Santiago', 'country': 'Chile', 'facility': 'Investigational Site Number : 1520002', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '7640881', 'city': 'Santiago', 'state': 'Reg Metropolitana de Santiago', 'country': 'Chile', 'facility': 'Investigational Site Number : 1520003', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '8330034', 'city': 'Santiago', 'state': 'Reg Metropolitana de Santiago', 'country': 'Chile', 'facility': 'Investigational Site Number : 1520010', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '8380456', 'city': 'Santiago', 'state': 'Reg Metropolitana de Santiago', 'country': 'Chile', 'facility': 'Investigational Site Number : 1520011', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '8380465', 'city': 'Santiago', 'state': 'Reg Metropolitana de Santiago', 'country': 'Chile', 'facility': 'Investigational Site Number : 1520005', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '8420383', 'city': 'Santiago', 'state': 'Reg Metropolitana de Santiago', 'country': 'Chile', 'facility': 'Investigational Site Number : 1520001', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '2530900', 'city': 'Viña del Mar', 'state': 'Región de Valparaíso', 'country': 'Chile', 'facility': 'Investigational Site Number : 1520006', 'geoPoint': {'lat': -33.02457, 'lon': -71.55183}}, {'zip': '2687000', 'city': 'Talcahuano', 'country': 'Chile', 'facility': 'Investigational Site Number : 1520012', 'geoPoint': {'lat': -36.72494, 'lon': -73.11684}}, {'zip': '100034', 'city': 'Beijing', 'country': 'China', 'facility': 'Investigational Site Number : 1560042', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '610072', 'city': 'Chengdu', 'country': 'China', 'facility': 'Investigational Site Number : 1560060', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}, {'zip': '610091', 'city': 'Chengdu', 'country': 'China', 'facility': 'Investigational Site Number : 1560068', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}, {'zip': '400016', 'city': 'Chongqing', 'country': 'China', 'facility': 'Investigational Site Number : 1560057', 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}, {'zip': '400065', 'city': 'Chongqing', 'country': 'China', 'facility': 'Investigational Site Number : 1560065', 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}, {'zip': '510630', 'city': 'Guangzhou', 'country': 'China', 'facility': 'Investigational Site Number : 1560058', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '250014', 'city': 'Jinan', 'country': 'China', 'facility': 'Investigational Site Number : 1560059', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}}, {'zip': '518026', 'city': 'Shenzhen', 'country': 'China', 'facility': 'Investigational Site Number : 1560064', 'geoPoint': {'lat': 22.54554, 'lon': 114.0683}}, {'zip': '92160', 'city': 'Antony', 'country': 'France', 'facility': 'Investigational Site Number : 2500008', 'geoPoint': {'lat': 48.75329, 'lon': 2.29668}}, {'zip': '44093', 'city': 'Nantes', 'country': 'France', 'facility': 'Investigational Site Number : 2500009', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'zip': '75010', 'city': 'Paris', 'country': 'France', 'facility': 'Investigational Site Number : 2500003', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '51100', 'city': 'Reims', 'country': 'France', 'facility': 'Investigational Site Number : 2500007', 'geoPoint': {'lat': 49.26526, 'lon': 4.02853}}, {'zip': '26102', 'city': 'Romans-sur-Isère', 'country': 'France', 'facility': 'Investigational Site Number : 2500010', 'geoPoint': {'lat': 45.0496, 'lon': 5.06602}}, {'zip': '48455', 'city': 'Bad Bentheim', 'country': 'Germany', 'facility': 'Investigational Site Number : 2760009', 'geoPoint': {'lat': 52.30066, 'lon': 7.15763}}, {'zip': '21614', 'city': 'Buxtehude', 'country': 'Germany', 'facility': 'Investigational Site Number : 2760014', 'geoPoint': {'lat': 53.46994, 'lon': 9.68968}}, {'zip': '20095', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Investigational Site Number : 2760017', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '24105', 'city': 'Kiel', 'country': 'Germany', 'facility': 'Investigational Site Number : 2762208', 'geoPoint': {'lat': 54.32133, 'lon': 10.13489}}, {'zip': '39104', 'city': 'Magdeburg', 'country': 'Germany', 'facility': 'Investigational Site Number : 2760018', 'geoPoint': {'lat': 52.13129, 'lon': 11.63189}}, {'zip': '55128', 'city': 'Mainz', 'country': 'Germany', 'facility': 'Investigational Site Number : 2760016', 'geoPoint': {'lat': 49.98185, 'lon': 8.28008}}, {'zip': '48149', 'city': 'Münster', 'country': 'Germany', 'facility': 'Investigational Site Number : 2762201', 'geoPoint': {'lat': 51.96236, 'lon': 7.62571}}, {'zip': '124 62', 'city': 'Athens', 'country': 'Greece', 'facility': 'Investigational Site Number : 3000004', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '161 21', 'city': 'Athens', 'country': 'Greece', 'facility': 'Investigational Site Number : 3000001', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '546 42', 'city': 'Thessaloniki', 'country': 'Greece', 'facility': 'Investigational Site Number : 3000002', 'geoPoint': {'lat': 40.64072, 'lon': 22.93493}}, {'zip': '564 29', 'city': 'Thessaloniki', 'country': 'Greece', 'facility': 'Investigational Site Number : 3000003', 'geoPoint': {'lat': 40.64072, 'lon': 22.93493}}, {'zip': '380016', 'city': 'Ahmedabad', 'country': 'India', 'facility': 'Investigational Site Number : 3560001', 'geoPoint': {'lat': 23.02579, 'lon': 72.58727}}, {'zip': '590002', 'city': 'Belagavi', 'country': 'India', 'facility': 'Investigational Site Number : 3560005', 'geoPoint': {'lat': 15.85212, 'lon': 74.50447}}, {'zip': '560090', 'city': 'Bengaluru', 'country': 'India', 'facility': 'Investigational Site Number : 3560008', 'geoPoint': {'lat': 12.97194, 'lon': 77.59369}}, {'zip': '160012', 'city': 'Chandigarh', 'country': 'India', 'facility': 'Investigational Site Number : 3560004', 'geoPoint': {'lat': 30.73629, 'lon': 76.7884}}, {'zip': '121002', 'city': 'Haryāna', 'country': 'India', 'facility': 'Investigational Site Number : 3560006', 'geoPoint': {'lat': 29.61611, 'lon': 76.98056}}, {'zip': '700073', 'city': 'Kolkata', 'country': 'India', 'facility': 'Investigational Site Number : 3560007', 'geoPoint': {'lat': 22.56263, 'lon': 88.36304}}, {'zip': '440015', 'city': 'Nagpur', 'country': 'India', 'facility': 'Investigational Site Number : 3560002', 'geoPoint': {'lat': 21.14631, 'lon': 79.08491}}, {'zip': '411057', 'city': 'Pune', 'country': 'India', 'facility': 'Investigational Site Number : 3560003', 'geoPoint': {'lat': 18.51957, 'lon': 73.85535}}, {'zip': '1834111', 'city': 'Afula', 'country': 'Israel', 'facility': 'Investigational Site Number : 3760004', 'geoPoint': {'lat': 32.60907, 'lon': 35.2892}}, {'zip': '8457108', 'city': 'Beersheba', 'country': 'Israel', 'facility': 'Investigational Site Number : 3760005', 'geoPoint': {'lat': 31.25181, 'lon': 34.7913}}, {'zip': '3109601', 'city': 'Haifa', 'country': 'Israel', 'facility': 'Investigational Site Number : 3760001', 'geoPoint': {'lat': 32.81303, 'lon': 34.99928}}, {'zip': '9112001', 'city': 'Jerusalem', 'country': 'Israel', 'facility': 'Investigational Site Number : 3760003', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'zip': '4920235', 'city': 'Petah Tikva', 'country': 'Israel', 'facility': 'Investigational Site Number : 3760006', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'zip': '4941492', 'city': 'Petah Tikva', 'country': 'Israel', 'facility': 'Investigational Site Number : 3760002', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'zip': '80-546', 'city': 'Gdansk', 'state': 'Pomeranian Voivodeship', 'country': 'Poland', 'facility': 'Investigational Site Number : 6160006', 'geoPoint': {'lat': 54.35227, 'lon': 18.64912}}, {'zip': '40-611', 'city': 'Katowice', 'state': 'Silesian Voivodeship', 'country': 'Poland', 'facility': 'Investigational Site Number : 6160003', 'geoPoint': {'lat': 50.2597, 'lon': 19.02173}}, {'zip': '31-209', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Investigational Site Number : 6162406', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '90-265', 'city': 'Lodz', 'country': 'Poland', 'facility': 'Investigational Site Number : 6160002', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}, {'zip': '20-607', 'city': 'Lublin', 'country': 'Poland', 'facility': 'Investigational Site Number : 6160004', 'geoPoint': {'lat': 51.25058, 'lon': 22.57009}}, {'zip': '11-041', 'city': 'Olsztyn', 'country': 'Poland', 'facility': 'Investigational Site Number : 6160011', 'geoPoint': {'lat': 53.78376, 'lon': 20.49272}}, {'zip': '33-100', 'city': 'Tarnów', 'country': 'Poland', 'facility': 'Investigational Site Number : 6160010', 'geoPoint': {'lat': 50.01381, 'lon': 20.98698}}, {'zip': '02-625', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Investigational Site Number : 6160009', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '02-962', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Investigational Site Number : 6160007', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '41944', 'city': 'Daegu', 'state': 'Daegu', 'country': 'South Korea', 'facility': 'Investigational Site Number : 4100008', 'geoPoint': {'lat': 35.87028, 'lon': 128.59111}}, {'zip': '15355', 'city': 'Ansan-si', 'state': 'Gyeonggi-do', 'country': 'South Korea', 'facility': 'Investigational Site Number : 4100002', 'geoPoint': {'lat': 37.32361, 'lon': 126.82194}}, {'zip': '13620', 'city': 'Seongnam-si', 'state': 'Gyeonggi-do', 'country': 'South Korea', 'facility': 'Investigational Site Number : 4100014', 'geoPoint': {'lat': 37.43861, 'lon': 127.13778}}, {'zip': '16499', 'city': 'Suwon', 'state': 'Gyeonggi-do', 'country': 'South Korea', 'facility': 'Investigational Site Number : 4100009', 'geoPoint': {'lat': 37.29111, 'lon': 127.00889}}, {'zip': '50612', 'city': 'Yangsan', 'state': 'Gyeongsangnam-do', 'country': 'South Korea', 'facility': 'Investigational Site Number : 4100003', 'geoPoint': {'lat': 35.34199, 'lon': 129.03358}}, {'zip': '21431', 'city': 'Bupyeong-gu', 'state': 'Incheon-gwangyeoksi', 'country': 'South Korea', 'facility': 'Investigational Site Number : 4100015'}, {'zip': '01812', 'city': 'Seoul', 'state': 'Seoul-teukbyeolsi', 'country': 'South Korea', 'facility': 'Investigational Site Number : 4100010', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '03080', 'city': 'Seoul', 'state': 'Seoul-teukbyeolsi', 'country': 'South Korea', 'facility': 'Investigational Site Number : 4100013', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '03722', 'city': 'Seoul', 'state': 'Seoul-teukbyeolsi', 'country': 'South Korea', 'facility': 'Investigational Site Number : 4100007', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '05030', 'city': 'Seoul', 'state': 'Seoul-teukbyeolsi', 'country': 'South Korea', 'facility': 'Investigational Site Number : 4100006', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '06591', 'city': 'Seoul', 'state': 'Seoul-teukbyeolsi', 'country': 'South Korea', 'facility': 'Investigational Site Number : 4100011', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '07804', 'city': 'Seoul', 'state': 'Seoul-teukbyeolsi', 'country': 'South Korea', 'facility': 'Investigational Site Number : 4100017', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '61453', 'city': 'Gwangju', 'country': 'South Korea', 'facility': 'Investigational Site Number : 4100012', 'geoPoint': {'lat': 35.15472, 'lon': 126.91556}}, {'zip': '833', 'city': 'Kaohsiung City', 'country': 'Taiwan', 'facility': 'Investigational Site Number : 1583201', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'zip': '402', 'city': 'Taichung', 'country': 'Taiwan', 'facility': 'Investigational Site Number : 1583202', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'zip': '100', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Investigational Site Number : 1580001', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Investigational Site Number : 1580003', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '333', 'city': 'Taoyuan', 'country': 'Taiwan', 'facility': 'Investigational Site Number : 1583203', 'geoPoint': {'lat': 24.99368, 'lon': 121.29696}}], 'overallOfficials': [{'name': 'Clinical Sciences & Operations', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Sanofi'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': "Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org"}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Sanofi', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}